|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
GAAD Medical Research Institute Inc. |
|---|---|
| Information provided by: | GAAD Medical Research Institute Inc. |
| ClinicalTrials.gov Identifier: | NCT00675077 |
Purpose
Huntington's disease (HD) is a fatal disease with profound neurological and behavioral features. HD is typically characterized by uncontrollable movements and psychological disturbances.
This study will investigate the use of far infrared radiation for control, management and treatment of HD.
| Condition | Intervention | Phase |
|---|---|---|
|
Huntington Disease |
Radiation: Far Infrared Radiation |
Phase I |
| Study Type: | Interventional |
| Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study |
| Official Title: | Phase 1 Study to Determine the Efficacy of Using Far Infrared Radiation for Control, Management and Treatment of HD |
| Estimated Enrollment: | 5 |
| Study Start Date: | May 2008 |
| Estimated Study Completion Date: | June 2010 |
| Estimated Primary Completion Date: | May 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
1: Experimental
Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
|
Radiation: Far Infrared Radiation
Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.
|
Observations from our research studies indicate that, far infrared rays provide energy to the body, improve the autonomic functions of the nervous system, restore the functions of the endocrine system, strengthen the immune system, improve blood circulation and increase the level of oxygen in the cells and promote the regeneration of muscle cells, nerves and brain cells.
It is hereby postulated that irradiation using far infrared, with wavelength between 5 to 20 microns, of the central nervous system, the endocrine system and the whole body could prevent, control, manage or possibly lead to complete rehabilitation of people who have HD.
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria: - People with HD Exclusion Criteria: - None
Contacts and Locations| Canada, Ontario | |
| The Centre for Incurable Diseases | |
| Toronto, Ontario, Canada, M4V 1L5 | |
| Principal Investigator: | Ken Nedd, M.D. | GAAD Medical Research Institute Inc. |
More Information
| Responsible Party: | GAAD Medical Research Institute Inc. ( Dr. Kwasi Donyina/Founder & President ) |
| Study ID Numbers: | GAAD-HD-CTP1 |
| Study First Received: | May 6, 2008 |
| Last Updated: | January 2, 2009 |
| ClinicalTrials.gov Identifier: | NCT00675077 History of Changes |
| Health Authority: | Canada: Health Canada |
|
Akinetic-Rigid Variant of Huntington Disease Chorea, Chronic Progressive Hereditary (Huntington) Chronic Progressive Hereditary Chorea (Huntington) Huntington Chorea |
Huntington Chronic Progressive Hereditary Chorea Huntington Disease, Akinetic-Rigid Variant Huntington Disease, Juvenile Huntington Disease, Juvenile-Onset |
|
Ganglion Cysts Basal Ganglia Diseases Muscle Rigidity Central Nervous System Diseases Brain Diseases Neurodegenerative Diseases Dyskinesias Cognition Disorders Chorea |
Delirium, Dementia, Amnestic, Cognitive Disorders Heredodegenerative Disorders, Nervous System Genetic Diseases, Inborn Mental Disorders Movement Disorders Dementia Huntington Disease Delirium |
|
Basal Ganglia Diseases Nervous System Diseases Central Nervous System Diseases Brain Diseases Neurodegenerative Diseases Dyskinesias Cognition Disorders Chorea |
Delirium, Dementia, Amnestic, Cognitive Disorders Heredodegenerative Disorders, Nervous System Genetic Diseases, Inborn Mental Disorders Movement Disorders Dementia Huntington Disease |
